Pfizer and Ranbaxy petition Supreme Court in Lipitor
Drugmakers accused of a pay-for-delay scheme have asked the US Supreme Court to review an appellate court’s decision that held plaintiffs do not need to calculate patent litigation costs to allege that a drugmaker cut an illegal deal with a generic competitor.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10